All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-01-02T16:22:57.000Z

What should supportive care look like for patients with chronic GvHD?

Jan 2, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in supportive care for GvHD.

Bookmark this article

During the GvHD Hub Steering Committee meeting in November 2022, key opinion leaders met to discuss what supportive care should look like for patients with chronic graft-versus-host disease (GvHD).

What should supportive care look like for patients with chronic GvHD?

The recorded discussion was chaired by Professor Amin Alousi (University of Texas MD Anderson Cancer Centre, Houston, US) and featured Mutlu Arat (Istanbul Florence Nightingale Hospital, Istanbul, TR), Ali Bazarbachi (American University of Beirut, Beirut, LB), Hildegard Greinix (Medical University of Graz, Graz, AT), and Attilio Olivieri (Ospedali Riuniti di Ancona, Ancona, IT).

Professor Alousi opens by highlighting the importance of supportive care in GvHD and the challenges in ensuring this is delivered effectively. This discussion focusses on the side effects and adverse events associated with GvHD treatments, including those that may have a negative impact on a patient’s quality of life.

The steering committee members discuss the need for a multidisciplinary approach to GvHD treatment through communication with other healthcare professionals (HCPs). For example, mental health professionals, pharmacists, and ophthalmologists may all be involved in the treatment of a patient with GvHD depending on the manifestation of the disease. The discussion concludes that cross-functional collaboration of HCPs may have a positive impact on quality of life and requires further research.

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox